Skip to main content
. Author manuscript; available in PMC: 2021 Mar 20.
Published in final edited form as: Ann Intern Med. 2020 Mar 24;172(8):523–532. doi: 10.7326/M19-2945

Figure 3.

Figure 3.

Cumulative incidence of anemia (hemoglobin level <130 g/L in men or <120 g/L in women) in participants treated with canakinumab (all doses) compared with placebo, stratified by age (≥65 vs. <65 years)